SecBot SecBot
Institutional Cluster

CYTK

CYTOKINETICS INC
NEUTRAL
Impact 3/10
Horizonweeks Processed7d 12h ago
Institutional cluster: 7 buyers, 3 sellers (bullish)
Actionable Insight • Neutral

Monitor Q4 2026 for aficamten sNDA filing in non-obstructive HCM and MYQORZO revenue trajectory. The institutional cluster is split (buyers vs sellers) and stale; next quarter's 13F will show whether the buying conviction held or reversed.

DirectionNeutral
Confidencemedium
Horizonweeks

MYQORZO

▲ Bullish Named in this fund cluster
Impact
Phase
Approved
Time to market
Already approved and commercializing in the U.S. (since December 2025) and Canada (October 2026). A label expansion decision from the FDA is expected November 14, 2026. A supplemental NDA for non-obstructive HCM is planned for submission in Q4 2026, with potential approval in 2027. EU submission is planned for early 2027.
Next catalyst
None dated

What to watchThe FDA decision on the MAPLE-HCM sNDA is due tomorrow, November 14, 2026. An approval would expand the label to include data showing aficamten's superiority over metoprolol, potentially strengthening the drug's positioning against standard-of-care beta blockers and BMS's Camzyos. A Complete Response Letter would be a negative surprise given the positive Phase 3 data. Separately, the supplemental NDA for non-obstructive HCM (ACACIA-HCM) is expected to be submitted in Q4 2026, which could be the next major catalyst.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$55.14
T+0 close · Nov 9, 2026 · via day close
Latest settled
−3.57%
T+5 · $53.17
Vs SPY
−1.88%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $55.14entry
  2. T+1 · 7d ago +1.89%α +2.25% · $56.18
  3. T+5 · 16h ago −3.57%α −1.88% · $53.17
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Seven institutional investors added or doubled CYTK positions in Q3 2026, accumulating $23.5M net, while three sellers reduced by $43.6M. The buying cluster follows strong Q3 MYQORZO revenue of $44.5M and a narrower net loss, but the 45-day reporting lag and absence of insider buying weaken the signal.

Key Financial Metrics

Direction
mixed
Buy Value
$80.3M
Sell Value
$43.6M
Net Flow
-$20.1M

Institutional Positions

Net institutional flow: -$20.1M

▲ Buyers (7)

InstitutionActionChangePosition ValueValue Δ
Aberdeen GroupDOUBLED+182.8%$22.3M$12.1M
BarclaysDOUBLED+205%$14.2M$8.2M
Candriam S.c.a.ADD+39.3%$40.8M$3.1M

▼ Sellers (3)

InstitutionActionChangePrev ValueValue Δ
CitigroupTRIM-73.9%$27.5M-$22.0M
Bank Of Montreal /CanNEAR_EXIT-79.8%$24.3M-$20.5M
Great Lakes AdvisorsTRIM-41.3%$2.0M-$1.1M

Key Facts

  • 7 institutional buyers added $23.5M in net new CYTK positions during Q3 2026
  • 3 institutional sellers reduced positions by $43.6M, led by Citigroup (-$22.0M) and Bank of Montreal (-$20.5M)
  • Top buyers: Aberdeen Group (+$12.1M), Barclays (+$8.2M), Candriam (+$3.1M)
  • All 10 institutions are asset managers; no activist, quant, or sovereign funds in the cluster
  • Confluence score of 20/100 indicates no insider buying to corroborate the institutional accumulation
  • Q3 2026 earnings (reported Nov 4) showed MYQORZO revenue of $44.5M and a narrower net loss of $190.1M

Financial Impact

7 institutions accumulated $23.5M in new positions while 3 reduced holdings by $43.6M, for a net institutional outflow of $20.1M

institutional_ownership

Risk Factors

  • 13F data is 45+ days stale; positions may have been unwound since quarter-end
  • No insider buying corroborates the institutional accumulation (confluence score 20/100)
  • Net institutional flow was negative ($20.1M outflow) despite 7 buyers, three large sellers dominated

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-CYTK-2026-Q3

Track record

46 reports on CYTK

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Viewing Entry $55.14 settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (10h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026